J. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. J. Clin. Oncol. 31, 1785–1791 (2013). 47. Janetzki, S., Cox, J. H., Oden, N. & Ferrari, G. Standardization and validation issues of the ELISPOT assay. Methods Mol. Biol. 302, 51–86 (2005). 48. Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytom. A 79, 167–174 (2011). 49. Love, M. I., Huber, W .